This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.To determine the safety, feasibility of administration, response and survival rates among patients with advanced colorectal cancer treated with the combination of drugs, Folfox6, Bevacizumab and Cetuximab.
Showing the most recent 10 out of 370 publications